citybiz.co
Cure8 news brief
Why This Matters
New leadership hires and a planned Phase 2 program mean prifemilast — an oral PDE4B-selective investigational drug — is moving toward larger IBD studies. People with IBD who want more oral treatment options or who follow pipeline drugs may find this relevant.
Who Should Pay Attention
Adult patients with ulcerative colitis or Crohn’s disease, clinicians and researchers focused on IBD drug development, and patients interested in emerging oral therapies.
Study Snapshot
Story typeBusiness news
Evidence typePhase 2 clinical trial
Source depthFull source text
What To Know
cAMPfield has appointed a new R&D leadership team and is preparing to advance prifemilast, an investigational oral PDE4B-selective inhibitor, into global Phase 2 trials for moderate-to-severe ulcerative colitis and Crohn’s disease.
The article summarizes executive hires and notes prior clinical experience for prifemilast, including evaluation in >700 participants and Phase 3 psoriasis data; it also mentions an exclusive licensing agreement for territories outside Greater China.
What to watch: Phase 2 study design details (endpoints, dosing, comparator, timelines, and eligibility) are not provided in this article. The piece focuses on corporate leadership and positioning rather than trial results or new clinical data.
If you are following prifemilast, look for upcoming company press releases or clinicaltrials.gov entries for specific trial protocols and timelines. No medical advice: This is company and industry reporting about drug development and personnel changes, not clinical guidance.
Decisions about treatment should be made with your clinician based on approved therapies and individual circumstances.
Keep In Mind
The article is a business/industry report about executive appointments and company strategy; it does not present new clinical trial results. Details about the Phase 2 trial design and confirmed timelines were not included here.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationcitybiz.co
AuthorsPaul Bluemner
Indexed viaGoogle News
Source typeWeb article
PublishedAug 3, 2026, 1:35 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Sanofi shows how $500M bowel disease bet compares to Merck and Roche's rival assets
The article reports new phase 2 trial data for duvakitug, an experimental anti‑TL1A treatment for ulcerative colitis and Crohn’s disease, which helps compare it to rival candidates and shapes upcoming phase 3 plans.
Teva, Sanofi present new results from RELIEVE UCCD Phase 2b study
New Phase 2b data were presented for duvakitug, an investigational antibody for UC and Crohn’s disease; people with IBD may see this as a potential future treatment option if later trials are positive. The report focuses...
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...